Numab Therapeutics AG’s Post

🌐 Bryan, Garnier & Co acts as Sole Global Coordinator & Joint Bookrunner on Egetis Therapeutics AB's SEK 300 million Follow-On Offering. More about the deal: https://lnkd.in/e9R8bdiv Egetis Therapeutics, a Swedish pharmaceutical company, is pioneering treatments for rare diseases in the orphan drug space. The proceeds will accelerate the development and commercialisation of Emcitate®, targeting MCT8 deficiency, a rare thyroid hormone transport disorder that severely impacts cognitive and physical development. 🤝 This is the third consecutive offering Bryan, Garnier & Co has led for Egetis Therapeutics since 2023, raising about SEK 1 billion in cumulated value and demonstrating Bryan, Garnier & Co’s dedicated commitment to supporting its clients. Special thanks to Nicklas Westerholm, Yilmaz M., and Karl Hård for their collaboration throughout this process. More about the deal: https://lnkd.in/e9R8bdiv Pierre Kiecolt-Wahl, Paul Lequeux, Hugo Fischer #Biotech #Rarediseases #MCT8 #Sweden

Delighted to have joined the OnHelix 2024 panel session on "New Horizons for Therapeutic Modalities". We explored a range of topics, and here are the main points I took away: 🤝 Multi-modality synergies 🤝 On the panel, we all agreed on the need for a diverse and comprehensive toolkit of different modalities, as there is no silver bullet. I would go one step further and say that different modalities can and should be combined to achieve greater impact. Think of mRNA (mRNA-4157 from Moderna) + antibody (Keytruda from Merck) for resected melanoma treatment. mRNA-4157 is a personalized neoantigen therapy that encodes up to 34 neoantigens derived from the patient's tumor mutational profile. When administered, these neoantigens are processed and presented by the body’s cells, triggering a tailored immune response specifically against the tumor. Keytruda works by enhancing the immune system's ability to detect and attack cancer cells by blocking the PD-1/PD-L1 pathway, which tumors use to evade immune detection. The synergistic action has shown promising results, with the combination therapy showing an 18-month recurrence-free survival 17% higher than monotherapy (see link in the comments below). 📈 More data doesn't mean better AI 📈 The cost of generating data in life sciences is dropping thanks to automation, making vast amounts of data available for both discovery and process automation. This treasure trove of data can be used to train AI/ML models to understand multifactorial diseases, develop advanced therapeutics, and optimize manufacturing processes to achieve better quality and economics. However, data accuracy, completeness, and standardization remain critical issues. The integration of data from disparate sources, each using different data standards and lacking semantic consistency, poses significant challenges. I came across a paper where the authors describe in detail how integrating different data sources with poor consistency actually decreases model accuracy to such an extent that it's not worth combining these sources if they are not aligned (see link in the comments below). 🕑 Move fast, break things...sort of 🕗 While cell and gene therapy manufacturing costs are rightly prioritized, the impact of development time on the overall economics of therapeutic development is equally significant. This issue was a focal point of the panel discussion, where panelists shared firsthand experiences and underscored the sluggishness of the design-build-test-learn cycle for CGT therapeutic development. Certainly, there isn't a single dominant cause of the slowdown; rather, several bottlenecks combine to delay progress and drive up costs. But if you had to choose one, which major bottleneck do you face most frequently in the discovery phase of new CGT? #ONHelix24 #CGT #mRNA

With so much interest in oral GLP-1s across the industry, now is the perfect time to dive into the biopharmaceutical considerations behind their development 🚀 I'm excited to share a link to our upcoming webinar, where we'll explore the key factors shaping this growing area of research. Don't miss this opportunity to hear from the experts and stay ahead in this rapidly evolving field! #QuotientSciences #Webinar #GLP1 #OralTherapeutics #DrugDevelopment

Get Stuck in at the Molecular Glue Drug Development You can expect to connect with 90+ industry glue peers from the likes of Degron Therapeutics, Plexium, AstraZeneca, GSK and many more at the premier forum dedicated entirely to advancements in molecular glue drug development. Over the course of three action-packed days, you'll engage with exclusive discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies. 📅👇Curious to learn more? Download our agenda here >>> https://ter.li/ed8hh4

Fascinating keynote panel by Miguel Forte from Kiji Therapeutics, Tara Sadeghi from Cellenkos, Inc. Seth Ettenberg from BlueRock Therapeutics and Katy Newton from Achilles Therapeutics plc talking about key considerations for ensuring commercial sustainability! #adtherapies24

Indeed, it was an interesting discussion about the #ATMP translation into commercialization and accessibility challenges. The comparability and robustness issues & with quality and safety in mind were mentioned as well. It is not always easy to have all the required expertise in house. Therefore the collaborative approach could be a good solution for the #ATMP developers.

Be sure to sign up on the below link for some lively discussion and interesting insights for tomorrow's webinar on Life Science virtual start-ups!

🚀 💹 Here's the latest Biotech fundraising updates from March 24..... ▶ Total number of investments: 10 ▶ Total sum invested: $1.819 Billion FogPharma [Series E] $145M Nocion Therapeutics, Inc. [Series B] $62M Sionna Therapeutics [Series C] $182M Alumis [Series C] $259M Tubulis GmbH [Series B2] $139M Engrail Therapeutics [Series B] $157M Clasp Therapeutics [Series A] $150M Capstan Therapeutics [Series B] $175M Mirador Therapeutics [Series A] $400M Avenzo Therapeutics [Series A] $150M Quality over quantity seems to be the strategy. The total number of investments isn't out of the ordinary but the amounts invested is significant. 73% more money invested compared to the month of February and 61% more than in January. Lots of reasons to be optimistic 🤑 💰

Hot of the Press! It’s been publications galore in the RAS world in 2024 and the past week has been no exception. Luckily enough, first and best-in-class therapies for CRC, pan-RAS approaches and non-canonical targets will be the hot topics filled with BRAND NEW DATA, exclusively at the 6th Annual RAS-Targeted Drug Development Summit (September 24 – 26, Boston, MA). Peers from Revolution Medicines, Amgen, Loxo@Lilly, Roche, GenFleet Therapeutics, Nested Therapeutics, Astellas Pharma, and 40+ more organizations are uniting to improve the standard of care for patients with unmet needs. Download the brochure now to see our topics of choice and find out how to join them: https://ter.li/8vhngl References: https://lnkd.in/eqznq5rM https://lnkd.in/eHYFStQE

3/4/24: Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX: Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026." More at https://lnkd.in/enMRx6NB